Brief: Caladrius Biosciences Provides Update On Phase 2B Freedom Trial Of Xowna® In Coronary Microvascular Dysfunction

Lisata Therapeutics

23/05/2022 21:21

May 23 (Reuters) - Caladrius Biosciences Inc  CLBS.O :
    * CALADRIUS BIOSCIENCES PROVIDES UPDATE ON PHASE 2B FREEDOM
TRIAL
OF XOWNA® IN CORONARY MICROVASCULAR DYSFUNCTION
    * CALADRIUS BIOSCIENCES - INTERIM ANALYSIS TO BE CONDUCTED
FOLLOWING ENROLLMENT SUSPENSION IN DOUBLE-BLIND, RANDOMIZED,
PLACEBO-CONTROLLED CLINICAL TRIAL
    * CALADRIUS BIOSCIENCES INC - NEXT DEVELOPMENT STEPS FOR
XOWNA TO
BE ANNOUNCED BY YEAR-END 2022 FOLLOWING REGULATORY AND BUSINESS
REVIEW
    * CALADRIUS BIOSCIENCES INC - SUSPENDED PATIENT ENROLLMENT
IN ITS
PHASE 2B STUDY OF XOWNA
    * CALADRIUS BIOSCIENCES INC - BELIEVES REVISED TIMELINE FOR
FREEDOM TRIAL IS NOT VIABLE FOR FINANCIAL AND COMMERCIAL REASONS

Source text for Eikon:  ID:nGNX6MC8RR 
Further company coverage:  CLBS.O 

 ((Reuters.Briefs@thomsonreuters.com;))